Performance characteristics of the LiBASys® des-gamma-carboxy prothrombin assay

Clinica Chimica Acta

Volumn 389, Issue 1-2, 2008, Pages 183-185

  Owen, William E ^a   Roberts, Richard F ^a   Roberts, William L ^b  

^a ARUP INSTITUTE FOR CLINICAL AND EXPERIMENTAL PATHOLOGY   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; DECARBOXYPROTHROMBIN;

AMINO TERMINAL SEQUENCE; ASSAY; CARBOXYLATION; HISTOLOGY; HUMAN; IMMUNOASSAY; LENTIL; LETTER; LIVER CELL CARCINOMA; PRIORITY JOURNAL; SENSITIVITY ANALYSIS;

ADULT; AGED; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; IMMUNOASSAY; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROTEIN PRECURSORS; PROTHROMBIN; REFERENCE VALUES; TUMOR MARKERS, BIOLOGICAL;

EID: 38649129093     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2007.11.031     Document Type: Letter

References (15)

1. Seeff L.B., and Hoofnagle J.H. Epidemiology of hepatocellular carcinoma in areas of low hepatitis B and hepatitis C endemicity. Oncogene 25 (2006) 3771-3777
2. El-Serag H.B. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 127 (2004) S27-S34
3. www.cancer.org/downloads/STT/CAFF2005f4PWSecured.pdf Date accessed 8/27/2007
4. Bruix J., and Sherman M. Management of hepatocellular carcinoma. Hepatology 42 (2005) 1208-1236
5. Fujiyama S., Tanaka M., Maeda S., et al. Tumor markers in early diagnosis, follow-up and management of patients with hepatocellular carcinoma. Oncology 62 (2002) 57-63 Review
6. Marrero J. Screening tests for hepatocellular carcinoma. Clin Liver Dis 9 (2005) 235-251
7. Liebman H.A., Furie B.C., Tong M.J., et al. Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med 310 (1984) 1427-1431
8. Zhou L., Liu J., and Luo F. Serum tumor markers for detection of hepatocellular carcinoma. World J Gastroenterol 28 (2006) 1175-1181
9. Koike Y., Shiratori Y., Sato S., et al. Des-γ-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma. Cancer 91 (2001) 561-569
10. Toyoda H., Kumada T., Kiriyama S., et al. Prognostic significance of simultaneous measurement of three tumor markers in patients with hepatocellular carcinoma. Clin Gastroenterol Hepatol 4 (2006) 111-117
11. Carr B.I., Kanke F., Wise M., et al. Clinical evaluation of lens culinaris agglutinin-reactive α-fetoprotein and des-γ-carboxy prothrombin in histologically proven hepatocellular carcinoma in the United States. Dig Dis Sci 52 (2007) 776-782
12. Grosley B.M., Hirchsauer C., Chambrette B., et al. Specific measurement of hypocarboxylated prothrombin in plasma or serum and application to the diagnosis of hepaocellular carcinoma. J Lab Clin Med 127 (1996) 553-564
13. Takatsu K., and Nakanishi T. Development and performance of an assay kit for PIVKA-II. Jpn J Clin Exp Med 73 (1996) 2656-2664
14. Ohhira M., Saito H., Suzuki Y., et al. A variant of des-γ-carboxy prothrombin was increased in alcoholic liver disease without hepatocellular carcinoma. Alcohol Clin Exp Res 25 (2001) 46S-50S
15. Naraki T., Kohno N., Saito H., et al. Gamma-carboxyglutamic acid content of hepatocellular carcinoma-associated des-gamma-carboxy prothrombin. Biochim Acta 1586 (2002) 287-298